Metformin Reduces CD4 T-Cell Exhaustion in HIV-Infected Adults on Suppressive Antiretroviral Therapy.
Increased negative checkpoint receptors (NCR) on T-cells are linked to T-cell exhaustion, dysfunctional effector responses, and HIV viral persistence. Metformin, an oral hypoglycemic agent used for diabetes, may have previously unrecognized beneficial immunologic effects. Using cryopreserved blood from a 24-week pilot study involving 12 virally-suppressed HIV-infected individuals randomized 1:1 to metformin vs observation (OBS), we assessed change in the frequencies of T-cell activation (CD38+HLA-DR+) and NCR (programmed cell death protein 1 [PD1], T-cell immunoreceptor with Ig and ITIM domains [TIGIT], and T-cell mucin-domain containing-3 [TIM3]). No differences in 24-week change were seen between arms in CD4 or CD8 T-cells, in the CD4/CD8 ratio, or in activated (CD38+HLA-DR+) CD4 or CD8 T-cells. However, metformin over 24 weeks led to decreases compared to OBS in single PD1+ (percent decrease: -9.6% vs 7.5%, p=0.015), in dual PD1+TIGIT+ (-15.0% vs 10.4%, p=0.002) and in triple PD1+TIGIT+TIM3+ (-24.0% vs 8.1%, p=0.041) CD4 T-cells. Metformin led to no changes in CD8 T-cell NCR frequencies. Metformin decreases the frequency of PD1+, PD1+TIGIT+ and PD1+TIGIT+TIM3+ expressing CD4 T-cells. This may have relevance to HIV cure strategies and to efforts to mitigate the risk of chronic complications of HIV.